drugset / Trial / NCT05679687
ThisCART19A Bridging to alloHSCT for R/R B-ALL
Phase 1
Unknown
20 enrolled
The First Affiliated Hospital of Soochow University
Fundamenta Therapeutics, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) bridging to HSCT in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r B-ALL).
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART19A | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |